Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

New study investigates use of microRNAs to identify primary brain tumours

Rosetta Genomics : 10 July, 2008  (Company News)
Rosetta Genomics has released the results of a study conducted by its scientists and collaborators that describes the use of microRNAs in accurately differentiating primary from metastatic tumours of the brain.
The study has been published online in the peer-reviewed journal Brain Pathology.

The findings demonstrate the potential of microRNAs to act as effective biomarkers that may be applied in a diagnostic test designed to identify primary tumours in patients with brain cancers.

'This latest study conducted by our scientists, as well as our previously published Nature Biotechnology paper, are further validation of microRNAs' vast potential to act as accurate biomarkers in various cancers,' noted Dr Dalia Cohen, chief scientific officer of Rosetta Genomics. 'We are continually optimising our microRNA platform technologies to leverage them in the development of a wide range of microRNA-based diagnostics, primarily for cancer.'

The study results, published in Brain Pathology, describe the development and validation of microRNA expression profiles for characterization of brain malignancies. Rosetta Genomics' scientists measured microRNA expression in RNA extracted from hundreds of formalin-fixed, paraffin-embedded (FFPE) samples of brain primary tumours and various other tissues, as well as 60 samples of metastatic brain tumours. Two microRNAs, miR-92b and miR-9/9, were found to be over-expressed in brain primary tumours, and may represent potential biomarkers for the identification of brain primary tumours.

The paper demonstrates, based on a blinded test set, that the overall sensitivity and specificity of this classifier are approximately 90 percent.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo